Research programme: psoriasis therapy - OSI Pharmaceuticals/Pfizer

Drug Profile

Research programme: psoriasis therapy - OSI Pharmaceuticals/Pfizer

Alternative Names: Psoriasis therapy research programme - OSI Pharmaceuticals/ Pfizer

Latest Information Update: 03 Aug 2006

Price : $50

At a glance

  • Originator OSI Pharmaceuticals; Pfizer
  • Class Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 03 Aug 2006 Discontinued - Preclinical for Psoriasis in USA (Topical)
  • 11 May 2006 No development reported - Preclinical for Psoriasis in USA (Topical)
  • 26 Jun 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top